All In Biotech

Drug Trial Radar · NCT06039449

A Study to Investigate the Prevention of COVID-19 WithVYD222 in Adults with Immune Compromise and in Participants Aged 12 Years or Older Who Are At Risk of Exposure to SARS-CoV-2

A Study to Evaluate the Efficacy and Safety of VYD222 for Prevention of COVID-19 (CANOPY)

Last checked: Nov 19, 2026Latest source record: Dec 9, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 790 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

790

Actual

Start

Sep 8, 2023

Primary completion

Nov 19, 2024

Study completion Nov 19, 2024

Sponsor

Lead sponsor
Invivyd, Inc.Industry
Sponsor type
Industry
First posted
Sep 15, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A study to investigate the prevention of COVID-19 with VYD222 in adults with immune compromise and in participants aged 12 years or older who are at risk of exposure to SARS-CoV-2

Conditions

  • COVID-19
  • SARS-CoV-2

Interventions

  • VYD222 (pemivibart)Drug

    Participants will be dosed on Day 1 followed by redosing at Month 3 (approximately 90 days) with VYD222.

  • Normal salineDrug

    Participants will be dosed on Day 1 followed by redosing at Month 3 (approximately 90 days) with Placebo.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Cohort A - Incidence of treatment emergent adverse eventsTime frame: Through Month 12
  2. Cohort A - Ratio of SARS-CoV-2 sVNA titer against a relevant variant following VYD222 administration at Day 28 compared to a prespecified SARS-CoV-2 sVNA titer threshold.Time frame: Day 28
  3. Cohort B - Incidence of treatment emergent adverse eventsTime frame: Through Month 12

Locations

18 sites in 1 country. Site status is shown where the registry gives one.

  • INVIVYD Investigative Site

    Fullerton, California

  • INVIVYD Investigative Site

    Long Beach, California

  • INVIVYD Investigative Site

    Rolling Hills Estates, California

  • INVIVYD Investigative Site

    San Diego, California

  • INVIVYD Investigative Site

    Clearwater, Florida

  • INVIVYD Investigative Site

    Miami, Florida

  • INVIVYD Investigative Site

    St. Petersburg, Florida

  • INVIVYD Investigative Site

    Atlanta, Georgia

  • INVIVYD Investigative Site

    Hinesville, Georgia

  • INVIVYD Investigative Site

    Oak Brook, Illinois

  • INVIVYD Investigative Site

    Silver Spring, Maryland

  • INVIVYD Investigative Site

    Burlington, Massachusetts

  • INVIVYD Investigative Site

    Morrisville, North Carolina

  • INVIVYD Investigative Site

    Salisbury, North Carolina

  • INVIVYD Investigative Site

    Edmond, Oklahoma

  • INVIVYD Investigative Site

    Yukon, Oklahoma

  • INVIVYD Investigative Site

    Beaumont, Texas

  • INVIVYD Investigative Site

    Dallas, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.